Anakinra as an IL-1 receptor pharmacological antagonist and lenzilumab as an anti-GM-CSF blockade antibody reduce the CRS and neurotoxicity by neutralizing these cytokines [190, 191]. The gene discussed is CSF2; the disease is congenital rubella syndrome.